摘要
目的观察博利康尼联合普米克令舒雾化吸入治疗毛细支气炎疗效。方法将62例毛细支气管炎患儿分为两组,治疗组31例,对照组31例。治疗组用博利康尼1毫升/次,联合普米克令舒1毫升/次,雾化吸入,对照组口服氨溴特罗口服液。对两组患儿临床症状、肺部体征消失时间及总有效率进行比较。结果治疗组在喘憋缓解、咳嗽、哮鸣音,湿啰音消失时间方面明显优于对照组(P<0.05);治疗组总有效率为96.77%,对照组总有效率为74.19%。治疗组总有效率明显高于对照组,经卡方检验(χ^2=4.68,P<0.05),有统计学意义。结论博利康尼联合普米克令舒雾化吸入治疗毛细支气管炎,疗效确切,能有效控制毛细支气管炎症状及体征,缩短病程,提高治愈率,治疗安全、有效、操作简便。
Objective To observe the efficacy of Bolikonil combined with Pulmicort Respules in the treatment of capillary bronchitis.Methods 62 children with bronchiolitis were divided into two groups,31 in the treatment group and 31 in the control group.The treatment group was treated with 1 ml/time of Bricanyl,1 mL/time with Pulmicort,and inhaled.The control group was orally administered with ambroxol.The clinical symptoms,disappearance time of lung signs and total effective rate were compared between the two groups.Results The treatment group was significantly better than the control group in the time of wheezing relief,cough,wheezing,and wet rales(P<0.05).The total effective rate was 96.77%in the treatment group and 74.19%.In the control group.The total effective rate of the treatment group was significantly higher than that of the control group.The chi-square test(χ^2=4.68,P<0.05)was statistically significant.Conclusion Boliconi combined with Pulmicort Respules in the treatment of bronchiolitis,the curative effect is clear,can effectively control the symptoms and signs of bronchiolitis,shorten the course of disease,improve the cure rate,safe,effective and easy to operate.
作者
贾春香
JIA Chun-xiang(Department of Pediatrics,Beijing Changping District Shahe Hospital,Beijing 102206,China)
出处
《中国医药指南》
2020年第12期63-64,共2页
Guide of China Medicine